Table 1.

Baseline demographics (treated patients)

	Afatinib (n = 41)
Age (years), median (range)	54 (30–86)
ECOG performance status, n (%)
0	24 (59)
1	14 (34)
2	3 (7)
Progesterone receptor-positive, n (%)	12 (29)
Estrogen receptor-positive, n (%)	20 (49)
Duration of prior trastuzumab (months), n (%)
≤6	3 (7.3)
6–12	10 (24.4)
12–36	20 (48.8)
>36	8 (19.5)
Best response to trastuzumab, n (%)
Complete response	2 (4.9)
Partial response	13 (31.7)
Stable disease	13 (31.7)
Progressive disease	9 (22.0)
Unknown	2 (4.9)
Not applicable	2 (4.9)
Number of prior chemotherapies
Median	3
Range	0–15
Other prior therapies; n (%)
Hormone	24 (59)
Radiotherapy	32 (78)
Surgery	38 (93)
Immunotherapy	23 (56)

ECOG Eastern Cooperative Oncology Group